Lantheus Holdings Inc (LNTH) valuation
Lantheus P/E ratio history
Lantheus trades at 24.0 times its earnings over the last twelve months and 17.1 times the earnings analysts expect over the next twelve. At its last 8 fiscal year ends its P/E ranged from 6.5 (year to Dec 2017) to 127.4 (year to Dec 2022), with a median of 17.3.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $66.55 | $3.41 | 19.5 | 12.0 |
| Dec 31, 2024 | $89.46 | $4.36 | 20.5 | 12.7 |
| Dec 31, 2023 | $62.00 | $4.65 | 13.3 | 10.3 |
| Dec 31, 2022 | $50.96 | $0.40 | 127.4 | 12.8 |
| Dec 31, 2021 | $28.89 | -$1.06 | n/m | — |
| Dec 31, 2020 | $13.49 | -$0.25 | n/m | — |
| Dec 31, 2019 | $20.51 | $0.79 | 26.0 | — |
| Dec 31, 2018 | $15.65 | $1.04 | 15.1 | — |
| Dec 31, 2017 | $20.45 | $3.15 | 6.5 | — |
| Dec 31, 2016 | $8.60 | $0.84 | 10.2 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Lantheus valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| LantheusLNTH | $6.54B | 24.0 | 17.1 | 4.2 |
| Ligand PharmaceuticalsLGND | $6.47B | 127.1 | 28.5 | 22.3 |
| Hims & Hers HealthHIMS | $6.41B | — | — | 2.5 |
| Rhythm PharmaceuticalsRYTM | $6.34B | — | — | 26.4 |
| Amneal PharmaceuticalsAMRX | $6.86B | 44.8 | 19.2 | 2.2 |
| Kodiak SciencesKOD | $6.21B | — | — | — |
| GrailGRAL | $6.16B | — | — | 37.3 |
| ImmunovantIMVT | $5.99B | — | — | — |
| Oruka TherapeuticsORKA | $5.84B | — | — | — |
| Peer median | 85.9 | 23.9 | 22.3 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: LNTH financials · LNTH returns
No forecast, no recommendation. This page describes Lantheus Holdings Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.